Delivery Order SPE2DR25D1100-SPE2DR26FDB4N
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,516.41 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on January 21, 2026, with an ultimate completion date of January 22, 2026. This firm fixed-price contract, which carries no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,035.99 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30 count) on January 8, 2026, with a completion date of January 9, 2026. This is a firm fixed-price, non-set-aside contract with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania location. The award represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999...
- The Defense Logistics Agency awarded a delivery order valued at $12,886.87 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on January 16, 2026, with completion targeted for January 20, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s...
- The Defense Logistics Agency awarded a delivery order valued at $11,535.36 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical procurement for military and veteran healthcare systems. The delivery...
- The Defense Logistics Agency awarded a $3,619.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on January 22, 2026, with completion expected by January 23, 2026. This is a non-set-aside, competitively awarded contract with performance in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $17.5K to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packaging) on January 20, 2026, with an ultimate completion date of January 21, 2026. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and will be performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,229.57 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania and completion expected by January 26, 2026. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $32,253.76 to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Ondansetron ODT 8mg tablets in a 30-count package. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of February 4, 2026. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order valued at $18,830 to AmerisourceBergen Drug Corp on January 23, 2026, for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This non-set-aside, competitively awarded contract features firm fixed pricing and an ultimate completion date of January 26, 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. AmerisourceBergen Drug Corp operates as a...
- The Defense Logistics Agency awarded a delivery order valued at $26,945.66 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count) with an ultimate completion date of November 3, 2025. This competitive award, utilizing firm fixed price pricing, will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FDB4NDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $55,197.07 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count units) on January 23, 2026, with an ultimate completion date of January 26, 2026. This firm fixed-price, non-set-aside contract is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor providing essential medical supplies and medications to federal agencies. Ondansetron is an antiemetic medication commonly used in military and veteran healthcare systems to manage nausea and vomiting. The company's federal contracting demonstrates significant capability in fulfilling competitive pharmaceutical procurement requirements across multiple therapeutic domains for the Department of Defense and Defense Health Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $55.2k | 1/22/26 |